Trimetazidine

From WikiMD.org
Jump to navigation Jump to search

Trimetazidine (pronunciation: /triːmɛtəˈziːdiːn/) is a pharmacological agent used primarily in the treatment of angina pectoris. It is classified as an anti-ischemic (an agent that improves myocardial glucose utilization through inhibition of fatty acid metabolism) under the ATC code C01EB15.

Etymology

The term "Trimetazidine" is derived from its chemical structure, which consists of three methoxy groups (tri-meth) and an azidine group.

Pharmacology

Trimetazidine works by improving the metabolism of cells in the heart and brain. It is a selective inhibitor of the enzyme long-chain 3-ketoacyl CoA thiolase, which is involved in fatty acid oxidation. By inhibiting this enzyme, Trimetazidine shifts the energy substrate preference from fatty acids to glucose, which requires less oxygen to be metabolized. This shift in metabolism reduces the severity and frequency of angina attacks.

Clinical Use

Trimetazidine is used as a long-term treatment of angina pectoris, and can be used in combination with other anti-anginal drugs. It is also used in vertigo, tinnitus, and Meniere's disease.

Side Effects

Common side effects of Trimetazidine include nausea, vomiting, abdominal pain, and headache. In rare cases, it can cause Parkinsonism.

Related Terms

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski